Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RNAC Stock Forecast 2025-2026
$6.88
Current Price
$178.90M
Market Cap
Buy 6
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to RNAC Price Targets
+539.5%
To High Target of $44.00
+466.9%
To Median Target of $39.00
+132.6%
To Low Target of $16.00
RNAC Price Momentum
-8.1%
1 Week Change
-12.6%
1 Month Change
-72.6%
1 Year Change
-61.6%
Year-to-Date Change
-74.0%
From 52W High of $26.50
+15.1%
From 52W Low of $5.98
📊 TOP ANALYST CALLS
Did RNAC Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cartesian is one of their latest high-conviction picks.
Latest RNAC Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, RNAC has a bullish consensus with a median price target of $39.00 (ranging from $16.00 to $44.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $6.88, the median forecast implies a 466.9% upside. This outlook is supported by 6 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Julian Harrison at BTIG, projecting a 539.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RNAC Analyst Ratings
6
Buy
2
Hold
0
Sell
RNAC Price Target Range
Low
$16.00
Average
$39.00
High
$44.00
Current: $6.88
Latest RNAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RNAC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 19, 2025 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Maintains | $30.00 |
| Nov 14, 2025 | BTIG | Julian Harrison | Buy | Maintains | $44.00 |
| Jul 9, 2025 | Wedbush | Martin Fan | Outperform | Initiates | $38.00 |
| May 8, 2025 | Needham | Gil Blum | Buy | Maintains | $40.00 |
| Apr 9, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $40.00 |
| Apr 9, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $40.00 |
| Mar 13, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Jan 28, 2025 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $45.00 |
| Jan 27, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Jan 13, 2025 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Dec 19, 2024 | BTIG | Julian Harrison | Buy | Initiates | $42.00 |
| Dec 4, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 3, 2024 | Needham | Buy | Reiterates | $N/A | |
| Nov 25, 2024 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Nov 8, 2024 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $41.00 |
| Oct 16, 2024 | Needham | Gil Blum | Buy | Reiterates | $41.00 |
| Sep 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $45.00 |
| Sep 4, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $45.00 |
Cartesian Therapeutics Inc. (RNAC) Competitors
The following stocks are similar to Cartesian based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cartesian Therapeutics Inc. (RNAC) Financial Data
Cartesian Therapeutics Inc. has a market capitalization of $178.90M with a P/E ratio of 2.0x. The company generates $1.09M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is +16.8% quarter-over-quarter, while maintaining an operating margin of -4,660.6% and return on equity of +1,138.3%.
Valuation Metrics
Market Cap
$178.90M
Enterprise Value
$48.64M
P/E Ratio
2.0x
PEG Ratio
0.1x
Price/Sales
164.0x
Growth & Margins
Revenue Growth (YoY)
+16.8%
Gross Margin
N/A
Operating Margin
-4,660.6%
Net Margin
0.0%
EPS Growth
+16.8%
Financial Health
Cash/Price Ratio
+80.1%
Current Ratio
10.7x
Debt/Equity
-0.4x
ROE
+1,138.3%
ROA
-12.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cartesian Therapeutics Inc. (RNAC) Business Model
About Cartesian Therapeutics Inc.
What They Do
Develops RNA-engineered cell therapies for diseases.
Business Model
The company generates revenue by developing and commercializing its proprietary RNA-engineered cell therapies through clinical trials and partnerships. By leveraging its RNA Armory platform, Cartesian focuses on creating targeted treatments for cancer, autoimmune disorders, and respiratory conditions, which could lead to significant market opportunities upon successful commercialization.
Additional Information
Cartesian Therapeutics is positioned at the forefront of biotechnology innovation, with therapies in various stages of clinical development. The company's work is significant for its potential to revolutionize treatment modalities, and it reflects the increasing interest and investment in biotechnological advancements aimed at improving healthcare outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
66
CEO
Dr. Carsten Brunn Ph.D.
Country
United States
IPO Year
2016
Website
www.cartesiantherapeutics.comCartesian Therapeutics Inc. (RNAC) Latest News & Analysis
Latest News
Quick Summary
Cartesian Therapeutics (RNAC) retains a "Buy" rating due to advancements in its Descartes-08 mRNA CAR-T pipeline. Positive phase 2b data supports its phase 3 study for myasthenia gravis.
Why It Matters
The "Buy" rating and progress in the Descartes-08 mRNA CAR-T pipeline signal potential growth for Cartesian Therapeutics, particularly in underserved autoimmune markets, enhancing investor confidence.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Cartesian Therapeutics granted stock options to two new employees: 50,000 shares at $8.85 and 2,650 shares at $8.20. Options vest over four years and have a ten-year term.
Why It Matters
The issuance of stock options indicates confidence in attracting talent, potentially fostering innovation and growth, which can positively influence Cartesian Therapeutics' stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Strength Seen in Cartesian Therapeutics, Inc. (RNAC): Can Its 8.2% Jump Turn into More Strength?
1 month ago
Quick Summary
Cartesian Therapeutics, Inc. (RNAC) experienced a rise in share price with above-average trading volume, though earnings estimate revisions indicate potential weakness ahead.
Why It Matters
Cartesian Therapeutics' share price surge on high volume may indicate short-term trading interest, but declining earnings estimate revisions signal potential future weakness, affecting long-term outlook.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Cartesian Therapeutics granted a new employee an option for 9,700 shares at $10.34 each, vesting over four years. The option has a ten-year term, approved under Nasdaq rules.
Why It Matters
The grant of stock options indicates Cartesian Therapeutics' commitment to attracting talent, which could enhance innovation and operational success, potentially boosting shareholder value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Cartesian Therapeutics, Inc. (RNAC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
2 months ago
Quick Summary
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) participated in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, with CEO Carsten Brunn and CMO Milos Miljkovic.
Why It Matters
The announcement of Cartesian Therapeutics participating in a major healthcare conference signals potential visibility and interest in their pipeline, which could influence stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotech focused on cell therapy for autoimmune diseases, will participate in investor conferences in September 2025.
Why It Matters
Participation in investor conferences can boost visibility and credibility for Cartesian Therapeutics, potentially attracting more investment and impacting stock performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About RNAC Stock
What is Cartesian Therapeutics Inc.'s (RNAC) stock forecast for 2026?
Based on our analysis of 11 Wall Street analysts, Cartesian Therapeutics Inc. (RNAC) has a median price target of $39.00. The highest price target is $44.00 and the lowest is $16.00.
Is RNAC stock a good investment in 2026?
According to current analyst ratings, RNAC has 6 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RNAC stock?
Wall Street analysts predict RNAC stock could reach $39.00 in the next 12 months. This represents a 466.9% increase from the current price of $6.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cartesian Therapeutics Inc.'s business model?
The company generates revenue by developing and commercializing its proprietary RNA-engineered cell therapies through clinical trials and partnerships. By leveraging its RNA Armory platform, Cartesian focuses on creating targeted treatments for cancer, autoimmune disorders, and respiratory conditions, which could lead to significant market opportunities upon successful commercialization.
What is the highest forecasted price for RNAC Cartesian Therapeutics Inc.?
The highest price target for RNAC is $44.00 from Julian Harrison at BTIG, which represents a 539.5% increase from the current price of $6.88.
What is the lowest forecasted price for RNAC Cartesian Therapeutics Inc.?
The lowest price target for RNAC is $16.00 from at , which represents a 132.6% increase from the current price of $6.88.
What is the overall RNAC consensus from analysts for Cartesian Therapeutics Inc.?
The overall analyst consensus for RNAC is bullish. Out of 11 Wall Street analysts, 6 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $39.00.
How accurate are RNAC stock price projections?
Stock price projections, including those for Cartesian Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 11:26 AM UTC